このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

新たに診断された小児 HGG および DIPG ならびに再発性髄芽腫を治療するための CMV 抗原を標的とする PEP-CMV ワクチン

2026年11月16日 更新者:Nationwide Children's Hospital

新たに診断された小児高悪性度グリオーマ、びまん性内在性橋グリオーマ、および再発性髄芽腫に対するCMV抗原を標的とする新規ペプチドワクチン(PEP-CMV)の第2相試験

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).

PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.

Funding Source - FDA OOPD

調査の概要

詳細な説明

This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.

Within each stratum, the populations that may be used for analysis are defined as:

  • Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.
  • Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.

Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.

Strata II [CLOSED on 19Aug2026] and III: Patients with newly-diagnosed high-grade glioma [CLOSED on 19Aug2026] or DIPG may be enrolled any time within 42 days after completing radiation.

Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

研究の種類

介入

入学 (推定)

120

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • Children's Hospital Colorado
        • コンタクト:
        • 主任研究者:
          • Holly Lindsay, MD
    • District of Columbia
      • Washington D.C.、District of Columbia、アメリカ、20010
        • 募集
        • Children's National Medical Center
        • コンタクト:
        • 主任研究者:
          • Eugene Hwang
    • Florida
      • Miami、Florida、アメリカ、33155
    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • まだ募集していません
        • Ann & Robert H. Lurie Children's Hospital of Chicago
        • 主任研究者:
          • Ashley Plant, MD
        • コンタクト:
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • まだ募集していません
        • Dana-Farber Cancer Institute
        • 主任研究者:
          • Karen Wright, MD
        • コンタクト:
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • 募集
        • C.S. Mott Children's Hospital
        • コンタクト:
    • Missouri
      • St Louis、Missouri、アメリカ、63110
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • 募集
        • Duke Cancer Center
        • 主任研究者:
          • Daniel Landi, MD
        • コンタクト:
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • 募集
        • Cincinnati Children's Hospital Medical Center
        • 主任研究者:
          • Peter de Blank, MD
        • コンタクト:
      • Columbus、Ohio、アメリカ、43205
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • まだ募集していません
        • Children's Hospital of Philadelphia
        • コンタクト:
        • 主任研究者:
          • Michael J Fisher, MD
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • Texas Children's Hospital
        • コンタクト:
        • 主任研究者:
          • Patricia Baxter, MD
    • Washington
      • Seattle、Washington、アメリカ、98105
        • 募集
        • Seattle Children's Hospital
        • コンタクト:
        • 主任研究者:
          • Sarah Leary, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

3年~39年 (子、大人)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)

  1. Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment

  2. Diagnosis: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.

    • Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.

  3. Metastatic Disease: Patients with M+ disease are eligible.

  4. Performance Status:

    Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior Therapy:

    1. Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.

      For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.

      Patients must have had their last fraction of:

      • Craniospinal irradiation, total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
      • Focal irradiation > 4 weeks prior to enrollment
    2. Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment

    3. Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment

    4. Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.

    5. Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.

    6. Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.

    7. Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion

  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as:

      • ANC (Absolute neutrophil count) ≥ 1000/µl.
      • Platelets ≥ 100,000/µl. (may be supported)
      • Hemoglobin > 8 g/dL. (may be supported)
    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)
      • 6 to < 10 years: 1 (Male) 1 (Female)
      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)
      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)
      • ≥ 16 years: 1.7 (Male) 1.4 (Female)
    3. Adequate Liver Function Defined as

      • Total bilirubin ≤1.5 times institutional ULN
      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Adequate Neurological Function Defined as

      • Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
      • Patients with current seizure disorders may be enrolled if seizures are well- controlled on antiepileptic therapies.
    5. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for three months after drug cessation.

    6. Signed informed consent according to institutional guidelines must be obtained prior to enrollment.

Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II, CLOSED on 19Aug2026) and Newly-Diagnosed (DIPG) (stratum III)

  1. Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment

  2. Diagnosis

    1. Stratum II [CLOSED on 19Aug2026]: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27-altered DMG).

      • Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
      • Patients with primary spinal cord tumors are eligible
    2. Stratum III: Patients with a newly-diagnosed DIPG:

      • Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
      • Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.
  3. Metastatic Disease: Patients with M+ disease are eligible.

  4. Performance Status:

    Karnofsky ≥ 50 for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).

    Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.

    1. Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
    2. For HGG patients, Patients must have received radiotherapy at a standard dose of 54-59.4 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 42 days after the date definitive surgery.
    3. For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 42 days after the date of radiographic diagnosis or biopsy
    4. For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 45-54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%
    5. For patients with metastatic disease: Patients may have received standard dose CSI
  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as • ANC (Absolute neutrophil count) ≥ 1000/µl.

      • Platelets ≥ 100,000/µl. (may be supported)

      • Hemoglobin > 8 g/dL. (may be supported)

    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)

      • 6 to < 10 years: 1 (Male) 1 (Female)

      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)

      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)

      • ≥ 16 years: 1.7 (Male) 1.4 (Female)

    3. Adequate Liver Function Defined as:

      • Total bilirubin ≤1.5 times institutional ULN

      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Adequate Neurological Function Defined as:

Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

d. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

e. Signed informed consent according to institutional guidelines must be obtained prior to registration and for 3 months after drug cessation.

Exclusion Criteria for all strata:

  1. Pregnancy or Breast-Feeding:

    1. Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
    2. Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.
  2. Study Specific:

    1. Active infection requiring treatment
    2. Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
    3. Known immunosuppressive disease
    4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
    5. Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
    6. Patients receiving concomitant tumor-directed therapy
    7. Patients receiving any other investigational drug therapy.
    8. Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
    9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
    10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
    11. Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:PEP-CMV

Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1

他の名前:
  • TMZ

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

他の名前:
  • Td

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
4-mo PFS in patients with recurrent medulloblastoma
時間枠:4 months

To determine the progression-free survival (PFS) at 4 months in pediatric or young adult patients with recurrent medulloblastoma treated with PEP-CMV.

4 months
1-yr OS in patients with newly diagnosed DIPG
時間枠:one year

To estimate the 1-year Overall Survival (OS) distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV

one year
1-yr PFS in patients with newly diagnosed HGG
時間枠:one year

To estimate the 1-year Progression Free Survival (PFS) distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV

one year

二次結果の測定

結果測定
メジャーの説明
時間枠
ORR in patients with recurrent medulloblastoma
時間枠:From Day 1 of treatment through 30 days following end of protocol treatment

To determine the objective response rate (ORR) = partial response (PR) + complete response (CR) in patients with recurrent medulloblastoma treated with PEP-CMV

From Day 1 of treatment through 30 days following end of protocol treatment
PFS in patients with recurrent medulloblastoma
時間枠:one year

To determine the 1-year Progression Free Survival (PFS) in patients with recurrent Medulloblastoma treated with PEP-CMV.

one year
OS in patients with newly diagnosed HGG by PEP-CMV
時間枠:2 years

To determine the 2-year Overall Survival (OS) in patients newly diagnosed with HGG treated with PEP-CMV.

2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

協力者

捜査官

  • 主任研究者:Maryam Fouladi, MD、Nationwide Children's Hospital
  • スタディチェア:Daniel Landi, MD、Duke Cancer Center
  • スタディチェア:Eric M Thompson, MD、Washington University - St. Louis Children's Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年7月18日

一次修了 (推定)

2028年6月15日

研究の完了 (推定)

2030年6月15日

試験登録日

最初に提出

2021年10月15日

QC基準を満たした最初の提出物

2021年10月15日

最初の投稿 (実際)

2021年10月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する